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gene expression and activity in vitro. Oral consumption of PFE or
active compounds derived from PFE may be protective against
cartilage degradation in OA.
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Purpose: Miniperl is an alternative spliced form of perlecan,
a proteoglycan that has both structural and functional roles in
a variety of tissues including cartilage. Its sequence shares
the beginning part with perlecan domain I with exons 4 and
5 spliced out resulting in a frame shift and termination shortly
after. The resulting protein shares a portion identical to perlecan
and a unique amino acid sequence (AF479675). This study
addresses the protein characteristics of miniperl and provides a
tool to begin to study its function in both chondrogenesis and
in other tissues. Further characterization of this novel chimeric
protein will bring new information as to the role(s) that this
gene may have in development, normal cell and tissue function,
and disease. We used a system that takes the advantages
of BM40 signal peptide and GFP for protein monitoring. The
tripartite system contained coding sequences for BM40 signal
peptide, miniperl, and IRES-EGFP in two reading frames under
the control of CMV promoter. Miniperl has been characterized by
Western blot and immunoprecipitation with perlecan and miniperl
antibodies. Unlike perlecan, in labeling studies performed thus
far using osteoarthritic chondrocytes, miniperl does not have an
associated gylcosaminoglycan chain.
Methods: Several steps were performed to include the desired
components and prepare the miniperl sequence for insertion into
the dual expression vector (with GFP). The miniperl transcript
was first inserted into vector pcDNA6/V5-His, then subcloned
into the 3’-end of the BM40 signal peptide gene sequence
in another vector pCEP-Pu/BMs.The BM40-miniperl-V5-His tag
gene sequences were then cloned into pFM2.2 vector. The vector
is designated as pFM-BM40-miniperl-V5-His. It was grown in E.
coli GC5 cells, prepared with a Qiagen endo-free DNA prep kit.
Human chondrocytes were isolated from osteoarthritis patients’
cartilage obtained from NDRI using IRB-approved protocols.
Chondrocytes were isolated by routine procedures using colla-
genase followed by culture in DMEM and grown in 5% CO2
at 37°C. Chondrocytes were cultured in suspension to maintain
their cartilage phenotype and transferred for 24 hr to adherent
conditions for transfection using the nucleofector kit (Amaxa Inc.).
Metabolic labeling and immunoprecipitation were performed with
35S-labeled sodium sulfate and cysteine-methionine. Rabbit poly-
clonal anti-miniperl antibodies were prepared to the unique pro-
tein sequence.
Results: The mammalian expression vector pFM-BM40-
miniperl-V5-His was successfully constructed and the correct
sequence confirmed by DNA sequencing. The unique properties
of this vector allow separate expression of the miniperl and GFP
permitting expression monitoring and cell analysis and sorting.
Human chondrocytes were transfected with cells in suspension
after a 24-hour period of adherence using the Amaxa nucleofec-
tor kit. Cell culture medium were harvested and analyzed.
Protein of 25-35 kDa is identified on Western blots using per-
lecan, anti-perlecan domain I-specific, and anti-miniperl antibod-
ies.
Immunoprecipitation with perlecan and miniperl specific antibod-
ies indicates the high level expression of miniperl and met/cys
labeled bands do not appear labeled with 35S-NaSO4 indicating
the lack of GAG.
Conclusions: In this study we generated an efficient construct
for the expression of miniperl in human chondrocytes. The tripar-
tite system of BM40 signal peptide, miniperl, and IRES-EGFP in
two reading frames under the control of CMV promoter proved
the high-level expression and easy detection. Unlike perlecan,
labeled miniperl does not have an associated gylcosaminoglycan
chain in osteoarthritic chondrocytes and additional studies will
demonstrate if this is consistent in normal chondrocytes and in
other tissues.
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Purpose: Recent studies showed a beneficial effect of COX-2
inhibition on proteoglycan turnover of both IL-1β/TNFα induced
cartilage damage as well as of osteoarthritic cartilage. Although
proteoglycan release and content normalized, proteoglycan syn-
thesis was only partially influenced. Because prostaglandin-E2
(PGE2) is the main product formed by COX-2, this suggests
prostaglandin-E2 to play an important role in disturbance a carti-
lage proteoglycan release but not synthesis, which was subject
of the present study.
Methods: Human healthy cartilage, alone or in the presence
of IL-1β+TNFα (200+800 pg/ml, resp.), was cultured for 7 days
with or without prostaglandin-E2 (3 up to 500 pg/ml) or the
selective COX-2 inhibitor (celecoxib 10 μM). Changes in cartilage
matrix proteoglycan turnover, prostaglandin-E2 and NO were
determined
Results: Proteoglycan synthesis and release of the cartilage
tissue were not affected by prostaglandin-E2 alone. Addition
of IL-1β+TNFα to the healthy cartilage resulted in inhibition
of proteoglycan synthesis and increased proteoglycan release
(p<0.05). When in combination with IL-1β+TNFα, prostaglandin-
E2 (200 pg/ml) was added proteoglycan release further increased
(p<0.05), but, proteoglycan synthesis was not further influenced.
Addition of a selective COX-2 inhibitor could reverse the ad-
verse characteristics of the combination of IL-1β/TNFα treated
normal cartilage. The effect was very clear for release, up to
almost complete normalization, whereas for synthesis the effect
was marginal. In these experiments, celecoxib was also able
to normalize the enhanced prostaglandin-E2-levels, whereas en-
hanced NO-levels remained elevated in the presence of cele-
coxib. Prostaglandin-E2 levels correlated significantly with pro-
teoglycan release (corr. coefficient: 0.499; p<0.000), whereas
NO levels correlated significantly with proteoglycan synthesis
(corr. coefficient: -0.626; p<0.000).
Conclusions: The present results suggest involvement of
prostaglandin-E2 in enhanced cartilage proteoglycan release,
although healthy cartilage has to be sensitized by IL-1β/TNFα.
IL-1β/TNFα induced NO seems to be more involved in inhibition
of proteoglycan synthesis, independent of prostaglandin-E2 and
with that insensitive to regulation by (selective) COX-2 inhibitors.
